Payment overview · 2025
General Payments
$661.32
32 reported records · 13 companies
Healthcare provider profile · identity verified
Freddy Gaton, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · ROBERTA, GA · NPI 1003896416
Verified facts
What the public records show
CMS Open Payments records show Freddy Gaton, M.D. received $661.32 in general payments during 2025 across 32 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Wegovy by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 315 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $184.70 | 27.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $85.95 | 13.0% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $66.58 | 10.1% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $59.73 | 9.0% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.14 | 8.3% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $50.76 | 7.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $46.65 | 7.0% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $25.01 | 3.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.57 | 3.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $21.61 | 3.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.94 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.08 | 2.1% | 1 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $13.60 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $661.32 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.95 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $85.95 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $66.58 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $63.96 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $50.76 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $36.55 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.39 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.39 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $25.01 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $21.61 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.26 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.94 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $13.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 252 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 343 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 222 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 190 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
150 | 29 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
49 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
122 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
252 | 60 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
58 | 18 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
343 | 65 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
20 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
190 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
222 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
96 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
315 | 61 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
27 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1632 | 221 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1290 | 312 |
| Amlodipine Besylate | Amlodipine Besylate | 1189 | 288 |
| Gabapentin | Gabapentin | 1179 | 223 |
| Lisinopril | Lisinopril | 886 | 207 |
| Omeprazole | Omeprazole | 859 | 192 |
| Alprazolam | Alprazolam | 850 | 101 |
| Losartan Potassium | Losartan Potassium | 847 | 184 |
| Tizanidine Hcl | Tizanidine Hcl | 840 | 164 |
| Levothyroxine Sodium | Levothyroxine Sodium | 716 | 153 |
| Furosemide | Furosemide | 642 | 173 |
| Prednisone | Prednisone | 625 | 312 |
| Metformin Hcl | Metformin Hcl | 598 | 139 |
| Pantoprazole Sodium | Pantoprazole Sodium | 591 | 139 |
| Simvastatin | Simvastatin | 574 | 126 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 521 | 141 |
| Trazodone Hcl | Trazodone Hcl | 497 | 97 |
| Buspirone Hcl | Buspirone Hcl | 493 | 99 |
| Metoprolol Succinate | Metoprolol Succinate | 480 | 106 |
| Meloxicam | Meloxicam | 478 | 121 |
| Carvedilol | Carvedilol | 466 | 103 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 458 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 451 | 113 |
| Duloxetine Hcl | Duloxetine Hcl | 443 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 354 | 74 |
| Jardiance | Empagliflozin | 343 | 65 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 328 | 239 |
| Potassium Chloride | Potassium Chloride | 327 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 318 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 317 | 125 |
| Tramadol Hcl | Tramadol Hcl | 316 | 70 |
| Eliquis | Apixaban | 315 | 61 |
| Famotidine | Famotidine | 312 | 72 |
| Sertraline Hcl | Sertraline Hcl | 311 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 309 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 308 | 68 |
| Hydrochlorothiazide | Hydrochlorothiazide | 305 | 75 |
| Allopurinol | Allopurinol | 304 | 68 |
| Azithromycin | Azithromycin | 270 | 197 |
| Quetiapine Fumarate | Quetiapine Fumarate | 263 | 42 |
| Nabumetone | Nabumetone | 257 | 143 |
| Farxiga | Dapagliflozin Propanediol | 252 | 60 |
| Dexamethasone | Dexamethasone | 241 | 174 |
| Mirtazapine | Mirtazapine | 232 | 44 |
| Lorazepam | Lorazepam | 225 | 34 |
| Ozempic | Semaglutide | 222 | 46 |
| Ibuprofen | Ibuprofen | 214 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 208 | 51 |
| Glimepiride | Glimepiride | 190 | 52 |
| Ondansetron Hcl | Ondansetron Hcl | 190 | 61 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 190 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 185 | 44 |
| Pregabalin | Pregabalin | 180 | 34 |
| Memantine Hcl | Memantine Hcl | 172 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 48 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 171 | 81 |
| Atenolol | Atenolol | 170 | 40 |
| Oxycodone Hcl | Oxycodone Hcl | 169 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 167 | 43 |
| Clonazepam | Clonazepam | 158 | 22 |
| Finasteride | Finasteride | 158 | 33 |
| Bupropion Hcl Sr | Bupropion Hcl | 156 | 44 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 156 | 40 |
| Fluconazole | Fluconazole | 155 | 87 |
| Promethazine Hcl | Promethazine Hcl | 152 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 150 | 39 |
| Linzess | Linaclotide | 150 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 147 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 144 | 36 |
| Glipizide | Glipizide | 141 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 135 | 25 |
| Januvia | Sitagliptin Phosphate | 133 | 28 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 125 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 45 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 94 |
| Myrbetriq | Mirabegron | 122 | 27 |
| Entresto | Sacubitril/Valsartan | 116 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 111 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 111 | 19 |
| Clindamycin Hcl | Clindamycin Hcl | 109 | 91 |
| Ezetimibe | Ezetimibe | 109 | 27 |
| Glipizide Er | Glipizide | 108 | 26 |
| Lamotrigine | Lamotrigine | 108 | 17 |
| Bupropion Xl | Bupropion Hcl | 103 | 23 |
| Mounjaro | Tirzepatide | 102 | 17 |
| Nystatin | Nystatin | 100 | 57 |
| Donepezil Hcl | Donepezil Hcl | 99 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 99 | 19 |
| Montelukast Sodium | Montelukast Sodium | 99 | 27 |
| Fenofibrate | Fenofibrate Nanocrystallized | 97 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 96 | 19 |
| Lovastatin | Lovastatin | 96 | 21 |
| Rybelsus | Semaglutide | 96 | 20 |
| Sucralfate | Sucralfate | 95 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 21 |
| Primidone | Primidone | 93 | 16 |
| Estradiol | Estradiol | 86 | 14 |
| Midodrine Hcl | Midodrine Hcl | 86 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 84 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 83 | 66 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 83 | 28 |
| Telmisartan | Telmisartan | 83 | 16 |
| Ondansetron Odt | Ondansetron | 80 | 22 |
| Risperidone | Risperidone | 80 | 14 |
| Clonidine Hcl | Clonidine Hcl | 78 | 15 |
| Xarelto | Rivaroxaban | 78 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 15 |
| Celecoxib | Celecoxib | 73 | 28 |
| Aripiprazole | Aripiprazole | 72 | 16 |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 72 | suppressed |
| Nifedipine Er | Nifedipine | 72 | 18 |
| Diazepam | Diazepam | 70 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 70 | 15 |
| Metformin Hcl Er | Metformin Hcl | 69 | 18 |
| Fenofibrate | Fenofibrate | 68 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 16 |
| Spironolactone | Spironolactone | 66 | 17 |
| Topiramate | Topiramate | 66 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 14 |
| Levetiracetam | Levetiracetam | 64 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 63 | 14 |
| Benazepril Hcl | Benazepril Hcl | 60 | 12 |
| Azelastine Hcl | Azelastine Hcl | 59 | 21 |
| Morphine Sulfate Er | Morphine Sulfate | 59 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 37 |
| Symbicort | Budesonide/Formoterol Fumarate | 58 | 18 |
| Valacyclovir | Valacyclovir Hcl | 56 | 32 |
| Alendronate Sodium | Alendronate Sodium | 53 | 11 |
| Megestrol Acetate | Megestrol Acetate | 53 | 17 |
| Propranolol Hcl | Propranolol Hcl | 53 | 11 |
| Tradjenta | Linagliptin | 53 | 13 |
| Lansoprazole | Lansoprazole | 52 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 51 | 17 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 33 |
| Gemfibrozil | Gemfibrozil | 49 | 11 |
| Synthroid | Levothyroxine Sodium | 49 | 11 |
| Baclofen | Baclofen | 48 | suppressed |
| Olanzapine | Olanzapine | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 14 |
| Metolazone | Metolazone | 47 | 26 |
| Levemir Flexpen | Insulin Detemir | 46 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 46 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 45 | 11 |
| Temazepam | Temazepam | 45 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | 17 |
| Amoxicillin | Amoxicillin | 43 | 33 |
| Bumetanide | Bumetanide | 43 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 43 | 23 |
| Methocarbamol | Methocarbamol | 42 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 41 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | 17 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 40 | suppressed |
| Metronidazole | Metronidazole | 40 | 14 |
| Terazosin Hcl | Terazosin Hcl | 40 | suppressed |
| Irbesartan | Irbesartan | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | 12 |
| Levofloxacin | Levofloxacin | 38 | 35 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Valsartan | Valsartan | 36 | 11 |
| Brilinta | Ticagrelor | 35 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 35 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 35 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 33 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 33 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 33 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 33 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Novolog Flexpen | Insulin Aspart | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Cilostazol | Cilostazol | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 27 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Vraylar | Cariprazine Hcl | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Ranolazine Er | Ranolazine | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 22 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 21 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Carbamazepine | Carbamazepine | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 20 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 17 |
| Trulicity | Dulaglutide | 20 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Modafinil | Modafinil | 19 | suppressed |
| Movantik | Naloxegol Oxalate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 11 |
| Novolin R Flexpen | Insulin Regular, Human | 19 | suppressed |
| Restasis | Cyclosporine | 19 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 18 | 18 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Nystop | Nystatin | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 17 | suppressed |
| Indomethacin | Indomethacin | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | 14 |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Wegovy | Semaglutide | 17 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Humulin R | Insulin Regular, Human | 16 | suppressed |
| Levemir | Insulin Detemir | 16 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 16 | 15 |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | 12 |
| Dutasteride | Dutasteride | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fosinopril-Hydrochlorothiazide | Fosinopril/Hydrochlorothiazide | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 14 | 14 |
| Sotalol Af | Sotalol Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 12 |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Trandolapril | Trandolapril | 13 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Oxytrol | Oxybutynin | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Probenecid | Probenecid | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $661.32 · 32 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, EVENITY, FARXIGA, IBSRELA, JARDIANCE, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, Veozah, Wegovy, Xelstrym, ZAVZPRET, ZORYVE | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error